Business Wire

Universal Peace Federation Launches “THINK TANK 2022” to Reunify Korean Peninsula During Virtual 6th Rally of Hope

11.5.2021 08:00:00 EEST | Business Wire | Press release

Share

World leaders and experts joined more than a million global participants for the launch of “Think Tank 2022” on May 9 KST during the virtual 6th Rally of Hope for the peaceful reunification of the Korean Peninsula.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510006060/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

José Manuel Barroso, former European Commission President addressing the global audience during the virtual 6th Rally of Hope and the launching of “THINK TANK 2022” (Photo: Business Wire)

The rally, sponsored by the Universal Peace Federation (UPF), was streamed live from South Korea to 194 nations and translated into 14 languages. Think Tank 2022 is a global multi-sector network of more than 2,000 experts from a wide range of fields—government, business, academia, faith, media, arts and culture—dedicated to the collaborative search for solutions to the world’s most critical challenges.

World-class leaders including the rally’s 12 keynote speakers affirmed and enhanced the concept of Think Tank 2022. “This network will make a difference for peace on the Korean Peninsula through international unity,” said Ban Ki-Moon, former United Nations Secretary-General and chairman of the new initiative. “I applaud Dr. Hak Ja Han Moon, UPF, and the leaders of Think Tank 2022.”

Former European Commission President José Manuel Barroso reminded the audience, that “peace also includes goodwill, trust and justice. The foundation of peace is each human being. The coronavirus taught us the lesson that we have to act and cooperate on a global scale.” “As leaders from around the world who cherish the values of faith, family, democracy and justice under law,” said former U.S. Vice President Mike Pence. “I commend you for coming together at this event to continue to sow the seeds of peace, believing that in time we will reap a harvest of peace that will benefit the people of Korea, the United States and all mankind.”

Born in present-day North Korea, UPF co-founders Dr. Hak Ja Han Moon and her late husband, Rev. Dr. Sun Myung Moon, fled to the south during the Korean War and have devoted their lives to advancing a more peaceful world and reuniting Korea. Think Tank 2022, will spearhead peacebuilding initiatives such as a UN Peace Park on the DMZ; building a Korea-Japan undersea tunnel; boosting Geumgang Mountain tourism development; and helping separated Korean families find their relatives.

“A reunified, denuclearized Korean Peninsula will bring massive peace and prosperity to the peninsula and to the region,” said Mike Pompeo, former U.S. Secretary of State and CIA Director. “Religious freedom is indeed the foundation of all freedoms...with prayer, faith, and commitment to the Lord, peace will follow.”

Many speakers, including former Republic of Korea Prime Minister Chung Sye-Kyun and Cambodian Prime Minister Hun Sen, praised the timeliness of Think Tank 2022 where “international cooperation and solidarity is needed now more than ever,” said Chung.

From Africa, Zanzibar President Dr. Hussein Ali Mwinyi recalled that Africans took part in the Korean War and long for peace and democracy in that region. The peaceful reunification of Korea will lead to “explosive growth,” said renowned American businessman and investor Mr. Jim Rogers. “If trains run through the DMZ and cars run on highways, there will be endless economic development opportunities...benefiting not only the two Koreas, but also China, Russia, Japan and Asia and the whole world.”

Mr. David Beasely, executive director of the United Nations World Food Programme, the world’s largest humanitarian organization and 2020 recipient of the Nobel Peace Prize, said, “This rally is reaching across continents, uniting people all over the world in a spirit of peace, mutual prosperity and public service.”

Governments have failed because they couldn’t go beyond “their bureaucracies, their biases, and their fears,” said Newt Gingrich, former U.S. Speaker of the House of Representatives. Think Tank 2022 offers a new way for people from multiple nations to work together “outside the traditional, formal structures” he said.

“Times of crisis often tend to be the moments of greatest opportunity,” said Mark Esper, former U.S. Secretary of Defense.

"Prof. Sarah Gilbert, co-developer of the Oxford/Astra-Zeneca vaccine said that great advances would result from the challenge of the pandemic, including much speedier development of vaccines to cope with new and mutant viruses. Much greater cooperation between nations was needed to ensure the effective roll-out of the currently available vaccines to nations afflicted by the pandemic as well as greater generosity on the part of richer nations to poorer ones".

The 6th Rally of Hope, part of a digital series started by Dr. Moon in August 2020, has brought together tens of millions of people worldwide who embrace freedom, peace, and unity based on the shared ideals of interdependence, mutual prosperity, and universal values. The Washington Times article on the rally is available here.

Rally of Hope Website (video with highlights of the event): https://www.rallyofhope.eu

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Peter Zoehrer, UPF Media Relations - Europe & Middle East
+43 (0)6645238794
media@europe.upf.org
UPF.ORG & EUME.UPF.ORG

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye